Predict your next investment

Embera NeuroTherapeutics company logo
HEALTHCARE | Drug Development
emberaneuro.com

See what CB Insights has to offer

Founded Year

2005

Stage

Grant - VI | Alive

Total Raised

$43.48M

About Embera NeuroTherapeutics

Embera NeuroTherapeutics is a clinical stage pharmaceutical company developing treatments for to potentially treat a range of addictions located in the greater Boston, MA area.

Embera NeuroTherapeutics Headquarter Location

365 Boston Post Road Suite 212

Sudbury, Massachusetts, 01776,

United States

978-579-4156

Latest Embera NeuroTherapeutics News

Embera NeuroTherapeutics Announces First Subject Dosed in Phase 2a Study of EMB-001 in Smoking Cessation

Jun 30, 2021

06/30/2021 | 07:31am EDT Message : Dennis Purcell, Founder of Aisling Capital, joins Board of Directors Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and potentially other addictions, today announced that the first subject has been dosed in a Phase 2a smoking cessation study for the treatment of tobacco use disorder. EMB-001 is designed to help patients struggling with addiction maintain abstinence and improve their quality of life by simultaneously targeting multiple neurological pathways that play a role in stress-induced, cue-induced and drug-induced addiction relapse. Embera also announced that Dennis Purcell, the Founder of Aisling Capital, has joined the Board of Directors. “Smoking cessation therapies have undoubtedly improved outcomes, however even when treated with the most successful approved interventions, over 75% of patients resume smoking within a year,” said Bruce McCarthy, M.D., Chief Medical Officer, Embera NeuroTherapeutics. “EMB-001 may reduce the neurophysiological activation of cues, stress and other triggers that lead to cigarette use in patients who are quitting smoking. This is an entirely new approach from marketed therapies, that could potentially be used in conjunction with approved therapies which work by blocking the ‘high’ of an addictive substance or by providing a substitute for the addictive substance. In a Phase 1 Safety study, EMB-001 was well-tolerated and signals of efficacy were observed. This Phase 2a study will help us better understand the efficacy of EMB-001 in helping subjects stop smoking.” The Phase 2a open label clinical trial will enroll between 25 and 50 subjects for a 12-week treatment period and Embera expects to report topline results in Q1 2022. Current investors in Embera participated in a $1.3 million financing to support the EMB-001 Phase 2a tobacco use disorder clinical study. Embera previously announced the initiation of a Phase 2 trial of EMB-001 in cocaine use disorder which is also expected to produce topline results in Q1 2022. Over 70% of subjects have been enrolled in the 80 subject cocaine use disorder trial. Embera also announced that Dennis Purcell, Founder of Aisling Capital LLC, has joined the Board of Directors. “Dennis Purcell brings an unparalleled record of accomplishment in biotech to the Board of Embera NeuroTherapeutics as the Company completes two important Phase 2 proof-of-concept clinical studies,” said Bob Linke, Executive Chairman of Embera. “Dennis’s role in the growth of the biotech industry has been widely recognized. He was inducted into the Biotech Hall of Fame by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry. We look forward to benefiting from Dennis’s expertise and experience as Embera advances EMB-001 through clinical development with the goal of providing a new treatment option for people fighting addictions.” Prior to founding Aisling Capital, a fund with over $1.8B in committed capital advancing healthcare technologies, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q for over 5 years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc. “Addiction remains a devastating disease in the United States and globally,” said Dennis Purcell. “EMB-001 has the potential to offer a new approach to treating addiction by reducing the cravings and loss of control that drive relapse. I look forward to working with the team at Embera as we advance EMB-001 in the clinic for the treatment of smoking cessation and cocaine addiction.” About EMB-001 EMB-001 is a patented combination product comprising two FDA-approved medications, the cortisol synthesis inhibitor metyrapone and the benzodiazepine oxazepam. The innovation is based on insights into the physiologic responses to stress in addiction. EMB-001 is thought to act by mechanisms distinct from those of existing addiction treatments and is hypothesized to reduce the increased activity in the stress response system induced by drugs, cues and stressors that contribute to relapse in addiction. EMB-001 may potentially reduce the cravings and loss of control that drive relapse in addiction, by uniquely targeting multiple pathways, thereby possibly maximizing potential efficacy. Therapies that reduce cravings and relapse and thus result in long-term abstinence and recovery would be significant contributions to the treatment of a broad range of addictions. About Embera NeuroTherapeutics Embera NeuroTherapeutics, Inc. is a clinical-stage pharmaceutical company focused on treating a broad range of addictions where the major clinical challenge is a limited range of effective therapies. Embera is developing a novel drug combination (EMB-001) targeting specific brain functions related to stress responses that drive craving and relapse associated with these disorders. Embera is advancing EMB-001 development programs in cocaine use disorder and smoking cessation. www.emberaneuro.com Note: The EMB-001 cocaine use disorder clinical research discussed in this press release was supported by the National Institute on Drug Abuse of the National Institutes of Health under grant number U01DA038879-01A1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. In addition, manufacturing of EMB-001 drug product for use in the Phase 2a tobacco use disorder clinical trial was supported by a grant from the Foundation for a Smoke Free World. View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005329/en/ © Business Wire 2021

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Embera NeuroTherapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Embera NeuroTherapeutics is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,731 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Embera NeuroTherapeutics Patents

Embera NeuroTherapeutics has filed 8 patents.

The 3 most popular patent topics include:

  • Anxiolytics
  • Benzodiazepines
  • Lactams
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/11/2015

6/5/2018

Lactams, Benzodiazepines, Pregnanes, Anxiolytics, Dosage forms

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/11/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/5/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Lactams, Benzodiazepines, Pregnanes, Anxiolytics, Dosage forms

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Embera NeuroTherapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Embera NeuroTherapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.